Abstract
The small-molecule inhibitor rigosertib acts as a RAS mimetic — by disrupting the association of RAS with RAF and other effector proteins, it inactivates RAS downstream signalling.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have